143 related articles for article (PubMed ID: 30796168)
21. Diagnostic value of 18F-FDG PET/CT for cutaneous extranodal natural killer/T-cell lymphoma, nasal type.
Liu C; Zhang Y; Zhang Y; Wang M; Liu R; Liu X; Hu S
Nucl Med Commun; 2016 May; 37(5):446-52. PubMed ID: 26657218
[TBL] [Abstract][Full Text] [Related]
22. Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial.
Iagaru A; Mittra E; Mosci C; Dick DW; Sathekge M; Prakash V; Iyer V; Lapa P; Isidoro J; de Lima JM; Gambhir SS
J Nucl Med; 2013 Feb; 54(2):176-83. PubMed ID: 23243299
[TBL] [Abstract][Full Text] [Related]
23. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
24. Comparison of 18F-FDG PET/CT scan and 99mTc-MDP bone scintigraphy in detecting bone metastasis in head and neck tumors.
Al-Bulushi NK; Abouzied ME
Nucl Med Commun; 2016 Jun; 37(6):583-8. PubMed ID: 26813992
[TBL] [Abstract][Full Text] [Related]
25. Oncologic 18F-FDG PET/CT: referring physicians' point of view.
Karantanis D; Kalkanis D; Allen-Auerbach M; Bogsrud TV; Subramaniam RM; Danielson A; Lowe VJ; Czernin J
J Nucl Med; 2012 Oct; 53(10):1499-505. PubMed ID: 22917886
[TBL] [Abstract][Full Text] [Related]
26.
Bouter C; Braune I; Meller B; Sahlmann C; Ritter C; Meller J
Nuklearmedizin; 2016 Dec; 55(6):242-249. PubMed ID: 27617327
[TBL] [Abstract][Full Text] [Related]
27. The clinical impact of
Hart A; Vali R; Marie E; Shaikh F; Shammas A
Pediatr Radiol; 2017 Oct; 47(11):1508-1513. PubMed ID: 28664453
[TBL] [Abstract][Full Text] [Related]
28. Whole-Body
Lebech AM; Gaardsting A; Loft A; Graff J; Markova E; Bertelsen AK; Madsen JL; Andersen KF; Benzon EV; Helms M; Mathiesen LR; David KP; Kronborg G; Kjaer A
J Nucl Med; 2017 Jul; 58(7):1058-1064. PubMed ID: 28082437
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of
Yellanki DP; Kothekar E; Al-Zaghal A; Cheng N; Werner TJ; Høilund-Carlsen PF; Alavi A
Hell J Nucl Med; 2018; 21(3):181-185. PubMed ID: 30411728
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
31. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
32. Determinants of diagnostic performance of 18F-FDG PET/CT in patients with fever of unknown origin.
Pereira AM; Husmann L; Sah BR; Battegay E; Franzen D
Nucl Med Commun; 2016 Jan; 37(1):57-65. PubMed ID: 26426966
[TBL] [Abstract][Full Text] [Related]
33. Multiple values of
Li Y; Zhou Y; Wang Q
Clin Rheumatol; 2017 Oct; 36(10):2297-2305. PubMed ID: 28831580
[TBL] [Abstract][Full Text] [Related]
34. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
[TBL] [Abstract][Full Text] [Related]
35. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
36. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Dual-Timepoint
Collarino A; Garganese G; Valdés Olmos RA; Stefanelli A; Perotti G; Mirk P; Fragomeni SM; Ieria FP; Scambia G; Giordano A; Rufini V
J Nucl Med; 2017 Dec; 58(12):1913-1918. PubMed ID: 28546331
[TBL] [Abstract][Full Text] [Related]
38. Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up
Taghipour M; Marcus C; Sheikhbahaei S; Mena E; Prasad S; Jha AK; Solnes L; Subramaniam RM
J Nucl Med; 2017 May; 58(5):737-743. PubMed ID: 27811123
[TBL] [Abstract][Full Text] [Related]
39. C-reactive protein levels can predict positive
Tsai HY; Lee MH; Wan CH; Yang LY; Yen TC; Tseng JR
J Microbiol Immunol Infect; 2018 Dec; 51(6):839-846. PubMed ID: 30190232
[TBL] [Abstract][Full Text] [Related]
40. The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods.
Moon SH; Cho SK; Kim WS; Kim SJ; Chan Ahn Y; Choe YS; Lee KH; Kim BT; Choi JY
J Nucl Med; 2013 Jul; 54(7):1039-44. PubMed ID: 23658217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
